Back
Halozyme Therapeutics Stock Price Chart
This Tech Company Grew 32,481%...
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
60
HALO
Halozyme Therapeutics
Last Price:
$60.55
Seasonality Move:
8.87%
7 Day Trial
ALL ACCESS PASS
$
7
-
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and HALO is experiencing buying pressure, which is a positive indicator for future bullish movement.
Halozyme Therapeutics Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 59.07 | Buy |
| 20-day SMA: | 60.18 | Buy |
| 50-day SMA: | 60.37 | Buy |
| 200-day SMA: | 55.92 | Buy |
| 8-day EMA: | 59.32 | Buy |
| 20-day EMA: | 59.94 | Buy |
| 50-day EMA: | 59.5 | Buy |
| 200-day EMA: | 54.75 | Buy |
Halozyme Therapeutics Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.54 | Sell |
| Relative Strength Index (14 RSI): | 51.34 | Buy |
| Chaikin Money Flow: | 655113 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (58.57 - 63.51) | Sell |
| Bollinger Bands (100): | (50.45 - 61.43) | Buy |
Halozyme Therapeutics Technical Analysis
| Apr 11 | Apr 14 | Apr 15 | Apr 16 | Apr 17 | Apr 21 | Apr 22 | Apr 23 | Apr 24 | Apr 25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr | ||||||||||
| 11 | 14 | 15 | 16 | 17 | 21 | 22 | 23 | 24 | 25 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Halozyme Therapeutics Stock
Is Halozyme Therapeutics Stock a Buy?
-
Halozyme Therapeutics share price is 60.49 while HALO 8-day simple moving average is 59.07, which is a Buy signal.
-
The stock price of HALO is 60.49 while Halozyme Therapeutics 20-day SMA is 60.18, which makes it a Buy.
-
Halozyme Therapeutics 50-day simple moving average is 60.37 while HALO share price is 60.49, making it a Buy technically.
-
HALO stock price is 60.49 and Halozyme Therapeutics 200-day simple moving average is 55.92, creating a Buy signal.
HALO Technical Analysis vs Fundamental Analysis
Buy
60
Halozyme Therapeutics (HALO)
is a Buy
Is Halozyme Therapeutics a Buy or a Sell?
-
Halozyme Therapeutics stock is rated a BuyThe current Halozyme Therapeutics [HALO] share price is $60.49. The Score for HALO is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.
Halozyme Therapeutics Stock Info
Market Cap:
7.4B
Price in USD:
60.49
Share Volume:
993K
Halozyme Therapeutics 52-Week Range
52-Week High:
66.00
52-Week Low:
37.97
Buy
60
Halozyme Therapeutics (HALO)
is a Buy
Halozyme Therapeutics Share Price Forecast
-
What is the Halozyme Therapeutics stock price today?The Halozyme Therapeutics stock price is 60.49 USD today.
-
Will HALO stock go up or go down?Halozyme Therapeutics> share price is forecast to RISE/FALL based on technical indicators
-
Is Halozyme Therapeutics overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Halozyme Therapeutics is not overvalued.
Is Halozyme Therapeutics Stock a Buy?
-
Halozyme Therapeutics share price is 60.49 while HALO 8-day exponential moving average is 59.32, which is a Buy signal.
-
The stock price of HALO is 60.49 while Halozyme Therapeutics 20-day EMA is 59.94, which makes it a Buy.
-
Halozyme Therapeutics 50-day exponential moving average is 59.50 while HALO share price is 60.49, making it a Buy technically.
-
HALO stock price is 60.49 and Halozyme Therapeutics 200-day simple moving average is 54.75, creating a Buy signal.
Fundamental Analysis of Halozyme Therapeutics
Is Halozyme Therapeutics a good investment?
-
Analysts estimate an earnings increase this quarter of $0.38 per share, a decrease next quarter of $0.03 per share, an increase this year of $0.87 per share, and an increase next year of $1.56 per share.
Technical Analysis of Halozyme Therapeutics
Should I short Halozyme Therapeutics stock?
-
HALO Moving Average Covergence Divergence (MACD) indicator is -0.54, suggesting Halozyme Therapeutics is a Sell
-
Halozyme Therapeutics Relative Strength Index (RSI) is 51.34, which suggest Halozyme Therapeutics is overbought
-
The Bollinger Bands (25) for Halozyme Therapeutics is (58.57 - 63.51), which suggest Halozyme Therapeutics is a Buy
-
The Bollinger Bands (100) for Halozyme Therapeutics is (50.45 - 61.43), which suggest Halozyme Therapeutics is a Buy
* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.